PRQR

ProQR TherapeuticsF

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

Current thesis

Composite grade F from latest DB weights. Momentum 33.5 / Value 41.1

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta +0.0.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

0 · Net Neutral

AI TargetsBase - · Bull - · Bear -

Data freshness

Prices

As of 2026-07-20

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-20 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-07-20

Supporting evidence

What

Grade F · Defensive

Confidence Medium · Net Neutral

Target $9.02

Why

Momentum34 · Δ7d -

Value41 · Δ7d +0.0

SentimentN/A · Δ7d -

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Value · See fundamentals

Momentum

40% active weight

Current posture

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Value

60% active weight

Current posture

7d trendFlat

Δ7d

+0.0

Δ21d

-0.1

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade F. Momentum 33.5 / Value 41.1

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$243.03M

Beta

0.20

Shares Out

138.09M

P/E (TTM) · Derived

-3.9

P/S (TTM)

11.41

P/FCF (TTM) · Derived

-3.12

Rev YoY

-50.0%

EPS YoY

+47.6%

Gross Margin

+79.7%

Op Margin

-276.4%

Net Debt

-$92.1M

Current Ratio

2.48

As of 2026-07-20 • Updated nightlySource: Internal modelMethodology